Nuclear translocation of YAP drives BMI‐associated hepatocarcinogenesis in hepatitis B virus infection

Hepatitis B virus (HBV) infection is a major cause of hepatocellular carcinoma (HCC) development and progression. The aim of this study was to mechanistically investigate the involvement of Hippo signalling in HBV surface antigen (HBsAg)‐dependent neoplastic transformation.

[1]  G. Gerken,et al.  Hippo Pathway Counter-Regulates Innate Immunity in Hepatitis B Virus Infection , 2021, Frontiers in Immunology.

[2]  J. Maris,et al.  Epigenetic regulator BMI1 promotes alveolar rhabdomyosarcoma proliferation and constitutes a novel therapeutic target , 2021, Molecular oncology.

[3]  Zhangzhi Zhu,et al.  Identification of potential crucial genes associated with the pathogenesis and prognosis of liver hepatocellular carcinoma , 2020, Journal of Clinical Pathology.

[4]  G. Gerken,et al.  Hepatitis B Virus Particles Activate Toll‐Like Receptor 2 Signaling Initially Upon Infection of Primary Human Hepatocytes , 2020, Hepatology.

[5]  Phillip A. Richmond,et al.  JASPAR 2020: update of the open-access database of transcription factor binding profiles , 2019, Nucleic Acids Res..

[6]  Li Ding,et al.  Integrated Proteogenomic Characterization of HBV-Related Hepatocellular Carcinoma , 2019, Cell.

[7]  Harlan R. Barker,et al.  Molecular Mechanisms Associated with ROR1-Mediated Drug Resistance: Crosstalk with Hippo-YAP/TAZ and BMI-1 Pathways , 2019, Cells.

[8]  K. Schmid,et al.  Intranuclear inclusions in hepatocellular carcinoma contain autophagy‐associated proteins and correlate with prolonged survival , 2019, The journal of pathology. Clinical research.

[9]  J. Llovet,et al.  Molecular therapies and precision medicine for hepatocellular carcinoma , 2018, Nature Reviews Clinical Oncology.

[10]  S. Alavian,et al.  Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. , 2018, The lancet. Gastroenterology & hepatology.

[11]  Steven J. M. Jones,et al.  Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma , 2017, Cell.

[12]  P. Schirmacher,et al.  Induction of Chromosome Instability by Activation of Yes-Associated Protein and Forkhead Box M1 in Liver Cancer. , 2017, Gastroenterology.

[13]  H. Hackstein,et al.  The tumor suppressor RASSF1A induces the YAP1 target gene ANKRD1 that is epigenetically inactivated in human cancers and inhibits tumor growth. , 2017, Oncotarget.

[14]  T. Tsai,et al.  Expression of a hepatitis B virus pre‐S2 deletion mutant in the liver results in hepatomegaly and hepatocellular carcinoma in mice , 2017, The Journal of pathology.

[15]  A. Iwama,et al.  The novel BMI-1 inhibitor PTC596 downregulates MCL-1 and induces p53-independent mitochondrial apoptosis in acute myeloid leukemia progenitor cells , 2017, Blood Cancer Journal.

[16]  G. Gerken,et al.  Hepatic expression of oncogenes Bmi1 and Dkk1 is up-regulated in hepatitis B virus surface antigen-transgenic mice in vivo and can be induced by treatment with HBV particles or lipopolysaccharides in vitro , 2016, Zeitschrift für Gastroenterologie.

[17]  Qing Xu,et al.  Nuclear accumulation of Yes-Associated Protein (YAP) maintains the survival of doxorubicin-induced senescent cells by promoting survivin expression. , 2016, Cancer letters.

[18]  H. Friess,et al.  Canonical NF‐κB signaling in hepatocytes acts as a tumor‐suppressor in hepatitis B virus surface antigen‐driven hepatocellular carcinoma by controlling the unfolded protein response , 2016, Hepatology.

[19]  T. Garg,et al.  Herbal and polymeric approaches for liver-targeting drug delivery: novel strategies and their significance , 2014, Drug delivery.

[20]  F. Camargo,et al.  Dynamic alterations in Hippo signaling pathway and YAP activation during liver regeneration. , 2014, American journal of physiology. Gastrointestinal and liver physiology.

[21]  M. Kudo,et al.  Quantitative Levels of Hepatitis B Virus DNA and Surface Antigen and the Risk of Hepatocellular Carcinoma in Patients with Hepatitis B Receiving Long-Term Nucleos(t)ide Analogue Therapy , 2014, Liver Cancer.

[22]  J. Kao,et al.  Persistence of hepatitis B virus covalently closed circular DNA in hepatocytes: molecular mechanisms and clinical significance , 2014, Emerging Microbes & Infections.

[23]  Chien-Jen Chen,et al.  Spontaneous seroclearance of hepatitis B seromarkers and subsequent risk of hepatocellular carcinoma , 2013, Gut.

[24]  L. Michaux,et al.  BMI1, The polycomb‐group gene, is recurrently targeted by genomic rearrangements in progressive B‐cell leukemia/lymphoma , 2013, Genes, chromosomes & cancer.

[25]  Ding‐Shinn Chen,et al.  Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads , 2013, Hepatology.

[26]  M. Caligiuri,et al.  Epigenetic silencing of microRNA-193a contributes to leukemogenesis in t(8;21) acute myeloid leukemia by activating the PTEN/PI3K signal pathway. , 2013, Blood.

[27]  S. Andò,et al.  CDK inhibitors (p16/p19/p21) induce senescence and autophagy in cancer-associated fibroblasts, “fueling” tumor growth via paracrine interactions, without an increase in neo-angiogenesis , 2012, Cell cycle.

[28]  Jun O. Liu,et al.  Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. , 2012, Genes & development.

[29]  T. Davis,et al.  BMI1 as a novel target for drug discovery in cancer , 2011, Journal of cellular biochemistry.

[30]  E. Lawlor,et al.  BMI-1 suppresses contact inhibition and stabilizes YAP in Ewing sarcoma , 2011, Oncogene.

[31]  Shridar Ganesan,et al.  BMI1 Is Recruited to DNA Breaks and Contributes to DNA Damage-Induced H2A Ubiquitination and Repair , 2011, Molecular and Cellular Biology.

[32]  Libing Song,et al.  Bmi-1 promotes invasion and metastasis, and its elevated expression is correlated with an advanced stage of breast cancer , 2011, Molecular Cancer.

[33]  W. Ryu,et al.  Hepatitis B Virus Polymerase Blocks Pattern Recognition Receptor Signaling via Interaction with DDX3: Implications for Immune Evasion , 2010, PLoS pathogens.

[34]  M. Levrero,et al.  Control of cccDNA function in hepatitis B virus infection. , 2009, Journal of hepatology.

[35]  Jiandie D. Lin,et al.  TEAD mediates YAP-dependent gene induction and growth control. , 2008, Genes & development.

[36]  Yi Zhang,et al.  Structure of a Bmi-1-Ring1B Polycomb Group Ubiquitin Ligase Complex* , 2006, Journal of Biological Chemistry.

[37]  M. Buendia,et al.  HBV induced carcinogenesis. , 2005, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[38]  Judith Campisi,et al.  The Bmi-1 oncogene induces telomerase activity and immortalizes human mammary epithelial cells. , 2002, Cancer research.

[39]  R. Palmiter,et al.  Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice , 1989, Cell.

[40]  Mengji Lu,et al.  Advanced Method for Isolation of Mouse Hepatocytes, Liver Sinusoidal Endothelial Cells, and Kupffer Cells. , 2017, Methods in molecular biology.

[41]  T. Garg,et al.  Stimuli-sensitive hydrogels: an excellent carrier for drug and cell delivery. , 2013, Critical reviews in therapeutic drug carrier systems.

[42]  K. Guan,et al.  A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF(beta-TRCP). , 2010, Genes & development.